Induced Pluripotent Stem Cells Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 – 2027)

The Induced Pluripotent Stem Cells Market is segmented by Derived Cell Type (Hepatocytes, Fibroblasts, Keratinocytes, Neurons and Others), Application (Drug Development, Regenerative Medicine, Toxicity Testing, Tissue Engineering and Cell Therapy), End User (Research Institutions and Other End Users) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Induced Pluripotent Stem Cells Market Size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 8.4 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Induced Pluripotent Stem Cells Market is projected to register a CAGR of 8.4% during the forecast period (2022 to 2027).

The healthcare system has witnessed enormous challenges due to the COVID-19 pandemic. All outpatient treatments were postponed or restricted during the COVID-19 pandemic to ​reduce the risk of viral transmission, as most chronic therapies were regarded as non-urgent. Several research studies were suspended during the COVID-19 period. However, research on the SARS-CoV-2 infection propelled significantly during the pandemic. An article titled “Induced pluripotent stem cell-based disease modeling and prospective immune therapy for coronavirus disease 2019,” published in the journal of Cytotherapy in March 2022, studied the modeling of SARS-CoV-2 infection in the human context to facilitate drug screening and discovery. With the various research studies being conducted on the use of human cell lines for vaccine development against the SARS-CoV-2 virus, the article showed that the iPSC-derived alveolar-type cells exposed to the SARS-CoV-2 virus would serve as an invaluable tool that can reproduce the genotypic and phenotypic aspects more closely associated with the infection.

Another article published in the International Journal of Molecular Science in December 2021, “Induced Pluripotent Stem Cells (iPSCs) and Gene Therapy: A New Era for the Treatment of Neurological Diseases,” studied the recent developments in innovative stem cell and gene editing therapeutic approaches. The article indicated that the iPSCs technology applied using the latest gene-editing methods (CRISPR-Cas9) represents the current emerging field. Clinical trials with iPSCs on the therapeutic application of stem cell therapy are associated with generating HLA-compatible iPSCs. The rise in studies involving induced pluripotent stem cells will likely propel the market’s growth in the forecast period.

In addition, the rise in the prevalence of personalized medicines for various disease treatments is adding to the growth of the induced pluripotent stem cell market. An article titled “Precision regenerative medicine,” published in the journal of Stem Cell Research & Therapy in January 2021, discussed the increase in precision or individualized medicine in the medical and surgical disciplines. The article showed that induced pluripotent stem cells are of great importance in the personalized medication segment, as they offer several advantages over other stem cells. Since the induced pluripotent stem cells for treating a person are grafted from the same person, donor variability is prevented, so autoimmune reactions to the treatment can be prevented. Moreover, the increasing number of cancer cases over the years is expected to contribute to the growth of the studied market. An article titled “Pluripotent Stem Cells: Cancer Study, Therapy, and Vaccination” presented in the journal of Stem Cell Reviews and Reports in June 2021 studied the role of pluripotent stem cells in cancer therapy. The article stated that the resemblance of cancer stem cells to pluripotent stem cells could provide an appropriate source of cancer stem cell-specific antigens through the cultivation of pluripotent stem cells, which brings to light, promising ideas for prophylactic and therapeutic cancer vaccine development. Thus, the rise in research studies involving cancer treatment using stem cell therapies adds to the market’s growth in the forecast period.

Additionally, in January 2022, Bayer’s BlueRock Therapeutics reported the dose administration for the first patient in Canada in partnership with the University Health Network in Phase 1 (Ph1), an open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease. The study evaluated the safety, tolerability, and preliminary efficacy of iPSC-derived dopaminergic neurons in Parkinson’s affected patients. Such studies involving induced pluripotent stem cells fuel market growth in the study period.

Thus, these aforementioned factors will likely bolster the market’s growth over the forecast period. However, a lack of awareness regarding stem cell therapies and higher treatment costs are projected to hinder the market’s growth.

Scope of the Report

Per the scope of this report, induced pluripotent stem cells are a type of stem cells that could be generated from a somatic cell. Induced pluripotent stem cells (iPSCS) are created by causing terminally differentiated somatic cells to revert to pluripotency by chemical or genetic reprogramming. The Induced Pluripotent Stem Cells Market is segmented by Derived Cell Type (Hepatocytes, Fibroblasts, Keratinocytes, Neurons, and Others), Application (Drug Development, Regenerative Medicine, Toxicity Testing, Tissue Engineering, and Cell Therapy), End User (Research Institutions and Other End Users) and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa and South America). The Market report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers values (in USD million) for the above segments.

By Derived Cell Type
Hepatocytes
Fibroblasts
Keratinocytes
Neurons
Others
By Application
Drug Development
Regenerative Medicine
Toxicity Testing
Tissue Engineering
Cell Therapy
Disease Modeling
By End User
Research Institutions
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Drug Development Segment is Expected to Hold a Major Market Share in the Induced Pluripotent Stem Cells Market.

By application, the drug development segment holds the major segment in the induced pluripotent stem cell market. Research focusing on drug development studies with induced pluripotent stem cells has been rising recently. For instance, an article titled "Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity Screening" published in the International Journal of Molecular Science in October 2020 discussed the broad use of iPSC-derived cardiomyocytes for drug development in terms of adverse drug reactions, mechanisms of cardiotoxicity, and the need for efficient drug screening protocols. Another article published in the Journal of Cells in December 2021, titled "Human Induced Pluripotent Stem Cell as a Disease Modeling and Drug Development Platform-A Cardiac Perspective," focused on methods to reprogram somatic cells into human-induced pluripotent stem cells and the solutions to overcome the immaturity of the human induced pluripotent stem cells derived cardiomyocytes from mimicking the structure and physiological properties of adult human cardiomyocytes to accurately model disease and test drug safety. Thus, this increase in the research of induced pluripotent stem cells for drug development and modeling will likely propel the segment's growth over the study period.

Furthermore, as per an article titled "Advancements in Disease Modeling and Drug Discovery Using iPSC-Derived Hepatocyte-like Cells," published in the Multi-Disciplinary Publishing Institute journal of Cells in March 2022, preserved differentiation and physiological function, amenability to genetic manipulation via tools such as CRISPR/Cas9, and availability for high-throughput screening, make induced pluripotent stem cell systems increasingly attractive for both mechanistic studies of disease and the identification of novel therapeutics. The article discussed the recent advancements in iPSC-based models of liver disease, including improvements in model system construction and the use of high-throughput screens for genetic studies and drug discovery. The study stated that the number of diseases that can be successfully modeled with hepatocyte-like cells derived from induced pluripotent stem cells is continually expanding, thereby developing a deeper understanding of various diseases and discovering new treatments for such diseases.

Several biotechnology companies have also focused on induced pluripotent cell-based drug therapies for various diseases. For instance, in February 2022, Edigene, Inc. and Neukio Biotherapeutics entered a research and development collaboration to develop next-generation immune cell therapies based on developing and manufacturing induced pluripotent stem cells (iPSC) and natural killer cells (NK Cell).

Thus, the abovementioned factors are altogether contributing to the segment's growth.

Induced Pluripotent Stem Cells Market Trends

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

The rise in the adoption of highly advanced technologies and systems in drug development, toxicity testing, and disease modeling, coupled with the growing acceptance of stem cell therapies in the region, are some of the major factors driving the market growth in North America.

In the United States, Food and Drug Administration in March 2022 discussed developing strategies to improve cell therapy product characterization. The agency focused on developing improved methods for testing stem cell products to ensure the safety and efficacy of such treatments when used as therapies. Likewise, in March 2020, the Food and Drug Administration announced that ImStem drug IMS001, which uses AgeX’s pluripotent stem cell technology, would be available for treating multiple sclerosis. Similarly, REPROCELL introduced a customized iPSC generation service in December 2020 and a new B2C website to promote the “Personal iPS” service. This service prepares and stores an individual’s iPSCs for future injury or disease regeneration treatment.

Thus, the increasing necessity for induced pluripotent stem cells coupled with increasing investment in the health care department is known to propel the market’s growth in this region.

Induced Pluripotent Stem Cells Market Analysis

Competitive Landscape

The Induced Pluripotent Stem Cells Market is competitive and consists of several major players. In terms of market share, a few major players are currently dominating the market. Some of the companies which are currently dominating the market are Axl Bioscience Ltd., Cynata Therapeutics Limited, Evotec SE, Fate Therapeutics, Inc., FUJIFILM Cellular Dynamics, Inc., Ncardia, Pluricell Biotech, REPROCELL USA, Inc., Sumitomo Dainippon Pharma Co., Ltd., Takara Bio, Inc., Thermo Fisher Scientific, Inc. ViaCyte, Inc., and others.

Recent Developments

  • In July 2022, Curi Bio, launched the Mantarray platform for human-relevant 3D heart and skeletal engineered muscle tissue (EMT) contractility analysis.
  • In May 2022, FUJIFILM Cellular Dynamics, Inc. launched Parkinson’s Disease iCell DopaNeurons featuring LRRK2 and GBA mutations, which are Parkinson's disease risk-associated mutations.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and market definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in Research and Development Activities in Stem Cells Therapies

      2. 4.2.2 Surge in Adoption of Personalized Medicine

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness Regarding Stem Cell Therapies

      2. 4.3.2 High Cost of Treatment

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Derived Cell Type

      1. 5.1.1 Hepatocytes

      2. 5.1.2 Fibroblasts

      3. 5.1.3 Keratinocytes

      4. 5.1.4 Neurons

      5. 5.1.5 Others

    2. 5.2 By Application

      1. 5.2.1 Drug Development

      2. 5.2.2 Regenerative Medicine

      3. 5.2.3 Toxicity Testing

      4. 5.2.4 Tissue Engineering

      5. 5.2.5 Cell Therapy

      6. 5.2.6 Disease Modeling

    3. 5.3 By End User

      1. 5.3.1 Research Institutions

      2. 5.3.2 Other End Users

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Axol Bioscience Ltd.

      2. 6.1.2 Cynata Therapeutics Limited

      3. 6.1.3 Evotec SE

      4. 6.1.4 Fate Therapeutics, Inc.

      5. 6.1.5 FUJIFILM Cellular Dynamics, Inc.

      6. 6.1.6 Ncardia

      7. 6.1.7 LizarBio Therapeutics (Pluricell Biotech)

      8. 6.1.8 REPROCELL USA, Inc.

      9. 6.1.9 Sumitomo Dainippon Pharma Co., Ltd.

      10. 6.1.10 Takara Bio, Inc.

      11. 6.1.11 Thermo Fisher Scientific, Inc.

      12. 6.1.12 ViaCyte, Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Induced Pluripotent Stem Cells Market market is studied from 2019 - 2027.

The Global Induced Pluripotent Stem Cells Market is growing at a CAGR of 8.4% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Axol Bioscience Ltd. , Cynata Therapeutics Limited , Evotec SE , FUJIFILM Cellular Dynamics, Inc. , Ncardia are the major companies operating in Global Induced Pluripotent Stem Cells Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!